Immune responses and reactogenicity after ChAdOx1 in individuals with past SARS-CoV-2 infection and those without

      We have read the article by E. Sansone, et al.
      • Sansone E.
      • Tiraboschi M.
      • sala E.
      • albini E.
      • lombardo M.
      • Castelli F.
      • et al.
      Effectiveness of BNT162b2 vaccine against the B.1.1.7 variant of SARS-CoV-2 among healthcare workers in Brescia, Italy.
      with great interest. The authors found the significant protective effect of BNT162b2 vaccination against SARS-CoV-2 infection and symptom development after SARS-CoV-2 infection among healthcare workers (HCWs). However, individuals with past natural infection with SARS-CoV-2 and those without may have different immune responses to COVID-19 vaccination. Some studies have quickly compared the immune responses to the mRNA-based vaccines between individuals with past infection with SARS-CoV-2 and those without
      • Anichini G.
      • Terrosi C.
      • Gandolfo C.
      • Gori Savellini G.
      • Fabrizi S.
      • Miceli G.B.
      • et al.
      SARS-CoV-2 antibody response in persons with past natural infection.
      • Prendecki M.
      • Clarke C.
      • Brown J.
      • Cox A.
      • Gleeson S.
      • Guckian M.
      • et al.
      Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine.
      • Krammer F.
      • Srivastava K.
      • Alshammary H.
      • Amoako A.A.
      • Awawda M.H.
      • Beach K.F.
      • et al.
      Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine.
      • Saadat S.
      • Rikhtegaran Tehrani Z.
      • Logue J.
      • Newman M.
      • Frieman M.B.
      • Harris A.D.
      • et al.
      Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2.
      ; but their kinetics in the adenovirus-vector-based vaccines remain unknown. In this study, we evaluated the immunogenicity and reactogenicity of the first dose of the adenovirus-vector-based ChAdOx1 nCoV-19 vaccine in HCWs with or without past infection with SARS-CoV-2.
      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Journal of Infection
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sansone E.
        • Tiraboschi M.
        • sala E.
        • albini E.
        • lombardo M.
        • Castelli F.
        • et al.
        Effectiveness of BNT162b2 vaccine against the B.1.1.7 variant of SARS-CoV-2 among healthcare workers in Brescia, Italy.
        J Infect. 2021 May 06; (PubMed PMID: 33965428. Pubmed Central PMCID: PMC8102078. Epub 2021/05/07. eng)
        • Anichini G.
        • Terrosi C.
        • Gandolfo C.
        • Gori Savellini G.
        • Fabrizi S.
        • Miceli G.B.
        • et al.
        SARS-CoV-2 antibody response in persons with past natural infection.
        N Engl J Med. 2021 Apr 14; (PubMed PMID: 33852796. Epub 2021/04/15. eng)
        • Prendecki M.
        • Clarke C.
        • Brown J.
        • Cox A.
        • Gleeson S.
        • Guckian M.
        • et al.
        Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine.
        Lancet. 2021 Mar 27; 397 (PubMed PMID: 33640037. Pubmed Central PMCID: PMC7993933. Epub 2021/03/01. eng): 1178-1181
        • Krammer F.
        • Srivastava K.
        • Alshammary H.
        • Amoako A.A.
        • Awawda M.H.
        • Beach K.F.
        • et al.
        Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine.
        N Engl J Med. 2021 Apr 8; 384 (PubMed PMID: 33691060. Pubmed Central PMCID: PMC8008743. Epub 2021/03/11. eng): 1372-1374
        • Saadat S.
        • Rikhtegaran Tehrani Z.
        • Logue J.
        • Newman M.
        • Frieman M.B.
        • Harris A.D.
        • et al.
        Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2.
        JAMA. 2021 Apr 13; 325 (PubMed PMID: 33646292. Pubmed Central PMCID: PMC7922233 Supplement during the conduct of the study. No other disclosures were reported. Epub 2021/03/02. eng): 1467-1469
        • Bae S.
        • Lee Y.W.
        • Lim S.Y.
        • Lee J.H.
        • Lim J.S.
        • Lee S.
        • et al.
        Adverse reactions following the first dose of ChAdOx1 nCoV-19 vaccine and BNT162b2 vaccine for healthcare workers in South Korea.
        J Korean Med Sci. 2021 May 3; 36 (PubMed PMID: 33942579. Pubmed Central PMCID: PMC8093607. Epub 2021/05/05): e115